Clinical Trial Update: Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial of eltanexor with Inqovi in high-risk myelodysplastic syndromes was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Eltanexor (eltanexor)
• Inqovi (decitabine/cedazuridine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-12-02